Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436)

PURPOSE: Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently demonstrated improved progression free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. The current study examined potential genetic markers associated with response and PFS in the ph...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nathanson, Katherine L., Martin, Anne-Marie, Wubbenhorst, Bradley, Greshock, Joel, Letrero, Richard, D’Andrea, Kurt, O’Day, Steven, Infante, Jeffrey R., Falchook, Gerald S., Arkenau, Hendrik-Tobias, Millward, Michael, Brown, Michael P., Pavlick, Anna, Davies, Michael A., Ma, Bo, Gagnon, Robert, Curtis, Martin, Lebowitz, Peter F., Kefford, Richard, Long, Georgina V.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3924894/
https://ncbi.nlm.nih.gov/pubmed/23833299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0827
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados